Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Previous studies demonstrated that the Ras suppressor,
RSU-1
, localizes to human chromosome 10p13, a region frequently deleted in high grade gliomas, and that
RSU-1
expression inhibited the tumorigenesis of a glioblastoma cell line. We have now examined RNA from human
glial tumors
for
RSU-1
expression by RT-PCR using primers for the 5' and 3' ends of the
RSU-1
open reading frame. Analysis of the amplified
RSU-1
cDNA demonstrated that in addition to the entire 858 bp
RSU-1
open reading frame, a shorter 725 bp
RSU-1
fragment was amplified as well. Sequencing of this product revealed that it encoded a
RSU-1
cDNA product which was missing a single 133 bp internal exon. This exon-deleted product was found in 30% of the high grade gliomas studied and 2/3 oligodendrogliomas, but not in other CNS tumors, bladder or colon tumors or normal tissue. The exon-deleted
RSU-1
product was infrequently detected in RNA from human tumor cell lines. Expression of an HA-tagged form of the deleted
RSU-1
protein in transfected Cos 1 cells revealed that the protein was unstable, with a half life of less than 1 h, in contrast to the full length HA-tagged Rsu-1 protein which was stable for more than 4 h. These results suggest that the alternative splicing of the
RSU-1
RNA to produce the exon-deleted form constitutes a mechanism for reduction or loss of functional Rsu-1. Because the expression of Rsu-1 can inhibit malignant growth of glioblastoma cells, the depletion of Rsu-1, via the production of the alternatively spliced form of
RSU-1
, may inhibit growth regulation in tumors.
...
PMID:Identification of an alternatively spliced RNA for the Ras suppressor RSU-1 in human gliomas. 1251 Jul 72